Page 415 - Williams Hematology ( PDFDrive )

390 Part V: Therapeutic Principles Chapter 24: Treatment of Infections in the Immunocompromised Host 391

5. Morrison V: Infections in patients with leukemia and lymphoma, in Infectious Compli- 34. Rolston KV, Besece D, Lamp KC, et al: Daptomycin use in neutropenic patients with
cations in Cancer Patients, edited by Stosor V, Zembower TR, p 319. Springer Interna- documented gram-positive infections. Support Care Cancer 22:7, 2014.
tional Publishing, Switzerland, 2014. 35. Wilcox MH, Corey GR, Talbot GH, et al: CANVAS 2: The second phase III, random-
6. Hachem R, Hanna H, Kontoyiannis D, et al: The changing epidemiology of invasive ized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with
candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia complicated skin and skin structure infections. J Antimicrob Chemother 65:iv53, 2010.
in hematologic malignancy. Cancer 112:2493, 2008. 36. Florescu I, Beuran M, Dimov R, et al: Efficacy and safety of tigecycline compared with
7. Chamilos G, Marom EM, Lewis RE, et al: Predictors of pulmonary zygomycosis versus vancomycin or linezolid for treatment of serious infections with methicillin-resistant
invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 41:60, 2005. Staphylococcus aureus or vancomycin-resistant enterococci: A phase 3, multicentre,
8. Walsh TJ, Gamaletsou MN: Treatment of fungal disease in the setting of neutropenia. double-blind, randomized study. J Antimicrob Chemother 62 (Suppl 1):i17, 2008.
Hematology Am Soc Hematol Educ Program 2013:423, 2013. 37. Boucher HW, Wilcox M, Talbot GH, et al: Once-weekly dalbavancin versus daily con-
9. Mikulska M, Del Bono V, Gandolfo N, et al: Epidemiology of viral respiratory tract ventional therapy for skin infection. N Engl J Med 370:2169, 2014.
infections in an outpatient haematology facility. Ann Hematol 93:669, 2014. 38. Awad SS, Rodriguez AH, Chuang YC, et al: A phase 3 randomized double-blind com-
10. Mori Y, Miyamoto T, Kato K, et al: Different risk factors related to adenovirus- or BK parison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of
virus-associated hemorrhagic cystitis following allogeneic stem cell transplantation. hospital-acquired pneumonia. Clin Infect Dis 2014.
Biol Blood Marrow Transplant 18:458, 2012. 39. Appelbaum PC: Reduced glycopeptide susceptibility in methicillin-resistant Staphylo-
11. Kamboj M, Sepkowitz KA: The risk of tuberculosis in patients with cancer. Clin Infect coccus aureus (MRSA). Int J Antimicrob Agents 30:398, 2007.
Dis 42:1592, 2006. 40. Rodvold KA, McConeghy KW: Methicillin-resistant staphylococcus aureus therapy:
12. De La Rosa GR, Jacobson KL, Rolston KV, et al: Mycobacterium tuberculosis at a com- Past, present, and future. Clin Infect Dis 58:S20, 2014.
prehensive cancer centre: Active disease in patients with underlying malignancy during 41. Beekmann SE, Gilbert DN, Polgreen PM, IDSA Emerging Infections Network: Toxicity
1990–2000. Clin Microbiol Infect 10:749, 2004. of extended courses of linezolid: Results of an Infectious Diseases Society of America
13. Chen CY, Sheng WH, Lai CC, et al: Mycobacterial infections in adult patients with Emerging Infections Network survey. Diagn Microbiol Infect Dis 62:407, 2008.
hematological malignancy. Eur J Clin Microbiol Infect Dis 31:1059, 2012. 42. DiazGranados CA, Jernigan JA: Impact of vancomycin resistance on mortality among
14. Sickles EA, Greene WH, Wiernik PH: Clinical presentation of infection in granulocy- patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 191:588,
topenic patients. Arch Intern MedIntern Med 135:715, 1975. 2005.
15. Chen CY, Cheng A, Huang SY, et al: Clinical and microbiological characteristics of 43. Kang Y, Vicente M, Parsad S, et al: Evaluation of risk factors for vancomycin-resistant
perianal infections in adult patients with acute leukemia. PLoS One 8:e60624, 2013. Enterococcus bacteremia among previously colonized hematopoietic stem cell trans-
16. Korones DN, Hussong MR, Gullace MA: Routine chest radiography of children with plant patients. Transpl Infect Dis 15:466, 2013.
cancer hospitalized for fever and neutropenia: Is it really necessary? Cancer 80:1160, 44. Smith PF, Birmingham MC, Noskin GA, et al: Safety, efficacy and pharmacokinetics
1997. of linezolid for treatment of resistant Gram-positive infections in cancer patients with
17. Heussel CP, Kauczor HU, Heussel G, et al: Early detection of pneumonia in febrile neu- neutropenia. Ann Oncol 14:795, 2003.
tropenic patients: Use of thin-section CT. AJR Am J Roentgenol 169:1347, 1997. 45. Rolston KV, Besece D, Lamp KC, et al: Daptomycin use in neutropenic patients with
18. Chen WT, Liu TM, Wu SH, et al: Improving diagnosis of central venous catheter-re- documented gram-positive infections. Support Care Cancer 22:7, 2014.
lated bloodstream infection by using differential time to positivity as a hospital-wide 46. Kelesidis T, Chow AL, Humphries R, et al: Case-control study comparing de novo and
approach at a cancer hospital. J Infect 59:317, 2009. daptomycin-exposed daptomycin-nonsusceptible Enterococcus infections. Antimicrob
19. Maschmeyer G, Beinert T, Buchheidt D, et al: Diagnosis and antimicrobial therapy of Agents Chemother 56:2150, 2012.
lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases 47. Cassir N, Rolain JM, Brouqui P: A new strategy to fight antimicrobial resistance: The
working party of the German Society of Haematology and Oncology. Eur J Cancer revival of old antibiotics. Front Microbiol 5:551, 2014.
45:2462, 2009. 48. Kim SH, Kwon JC, Choi SM, et al: Escherichia coli and Klebsiella pneumoniae bacte-
20. Cuenca-Estrella M, Meije Y, Diaz-Pedroche C, et al: Value of serial quantification remia in patients with neutropenic fever: Factors associated with extended-spectrum
of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive beta-lactamase production and its impact on outcome. Ann Hematol 92:533, 2013.
Aspergillosis in patients with febrile neutropenia. J Clin MicrobiolMicrobiology 47:379, 49. Rafailidis PI, Falagas ME: Options for treating carbapenem-resistant Enterobacteria-
2009. ceae. Curr Opin Infect Dis 27:479, 2014.
21. Gupta S, Sultenfuss M, Romaguera JE, et al: CT-guided percutaneous lung biopsies in 50. Nordmann P, Cuzon G, Naas T: The real threat of Klebsiella pneumoniae carbapene-
patients with haematologic malignancies and undiagnosed pulmonary lesions. Hema- mase-producing bacteria. Lancet Infect Dis 9:228, 2009.
tol Oncol 28:75, 2010. 51. Schiel X, Link H, Maschmeyer G, et al: A prospective, randomized multicenter trial
22. Freifeld AG, Bow EJ, Sepkowitz KA, et al: Clinical practice guideline for the use of of the empirical addition of antifungal therapy for febrile neutropenic cancer patients:
antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious Results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. Infec-
diseases society of America. Clin Infect Dis 52:e56, 2011. tion 34:118, 2006.
23. Bow EJ, Rotstein C, Noskin GA, et al: A randomized, open-label, multicenter com- 52. Jorgensen KJ, Gotzsche PC, Dalboge CS, Johansen HK: Voriconazole versus
parative study of the efficacy and safety of piperacillin-tazobactam and cefepime for amphotericin B or fluconazole in cancer patients with neutropenia. Cochrane Database
the empirical treatment of febrile neutropenic episodes in patients with hematologic Syst Rev 2:CD004707, 2014.
malignancies. Clin Infect Dis 43:447, 2006. 53. Walsh TJ, Teppler H, Donowitz GR, et al: Caspofungin versus liposomal amphotericin
24. Klastersky JA: Use of imipenem as empirical treatment of febrile neutropenia. Int J B for empirical antifungal therapy in patients with persistent fever and neutropenia. N
Antimicrob Agents 21:393, 2003. Engl J Med 351:1391, 2004.
25. Feld R, DePauw B, Berman S, et al: Meropenem versus ceftazidime in the treatment of 54. Johansen HK, Gotzsche PC: Amphotericin B lipid soluble formulations versus
cancer patients with febrile neutropenia: A randomized, double-blind trial. J Clin Oncol amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev
18:3690, 2000. 9:CD000969, 2014.
26. Raad II, Escalante C, Hachem RY, et al: Treatment of febrile neutropenic patients with 55. Spellberg B, Ibrahim AS: Recent advances in the treatment of mucormycosis. Curr
cancer who require hospitalization: A prospective randomized study comparing imi- Infect Dis Rep 12:423, 2010.
penem and cefepime. Cancer 98:1039, 2003. 56. Girmenia C, Cimino G, Di Cristofano F, et al: Effects of hydration with salt repletion on
27. Egerer G, Goldschmidt H, Salwender H, et al: Efficacy of continuous infusion of ceftaz- renal toxicity of conventional amphotericin B empirical therapy: A prospective study in
idime for patients with neutropenic fever after high-dose chemotherapy and peripheral patients with hematological malignancies. Support Care Cancer 13:987, 2005.
blood stem cell transplantation. Int J Antimicrob Agents 15:119, 2000. 57. O’Connor N, Borley A: Prospective audit of the effectiveness of hydrocortisone pre-
28. Zhanel GG, Wiebe R, Dilay L, et al: Comparative review of the carbapenems. Drugs medication on drug delivery reactions following amphotericin B lipid complex *. Curr
67:1027, 2007. Med Res Opin 25:749, 2009.
29. Paul M, Dickstein Y, Schlesinger A, et al: Beta-lactam versus beta-lactam-aminogly- 58. Cuenca-Estrella M, Arendrup MC, Chryssanthou E, et al: Multicentre determination of
coside combination therapy in cancer patients with neutropenia. Cochrane Database quality control strains and quality control ranges for antifungal susceptibility testing of
Syst Rev 6:CD003038, 2013. yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Test-
30. Bliziotis IA, Michalopoulos A, Kasiakou SK, et al: Ciprofloxacin vs an aminogly- ing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing
coside in combination with a beta-lactam for the treatment of febrile neutropenia: A (AFST-EUCAST). Clin Microbiol Infect 13:1018, 2007.
meta-analysis of randomized controlled trials. Mayo Clin Proc 80:1146, 2005. 59. Kim SJ, Cheong JW, Min YH, et al: Success rate and risk factors for failure of empirical
31. Klein EY, Sun L, Smith DL, Laxminarayan R: The changing epidemiology of methicil- antifungal therapy with itraconazole in patients with hematological malignancies: A
lin-resistant Staphylococcus aureus in the United States: A national observational study. multicenter, prospective, open-label, observational study in Korea. J Korean Med Sci
Am J Epidemiol 177:666, 2013. 29:61, 2014.
32. Klastersky J: Role of quinupristin/dalfopristin in the treatment of Gram-positive noso- 60. Walsh TJ, Pappas P, Winston DJ, et al: Voriconazole compared with liposomal
comial infections in haematological or oncological patients. Cancer Treat Rev 29:431, amphotericin B for empirical antifungal therapy in patients with neutropenia and per-
2003. sistent fever. N Engl J Med 346:225, 2002.
33. Falagas ME, Siempos II, Vardakas KZ: Linezolid versus glycopeptide or beta-lactam 61. Przepiorka D, Buadi FK, McClune B: Oral voriconazole for empiric antifungal treat-
for treatment of Gram-positive bacterial infections: Meta-analysis of randomised con- ment in patients with uncomplicated febrile neutropenia. Pharmacotherapy 28:58,
trolled trials. Lancet Infect Dis 8:53, 2008. 2008.

Kaushansky_chapter 24_p0383-0392.indd 390 9/17/15 5:58 PM